Form Release Summary – January 2026

Contents

General Updates

- **Updates made to applicable questions that include the wording 'date'.**
  - Update: Updated the question text from 'date' to 'date (parent question)' to reference the 'parent question'. For example, the question text was updated from 'date' to 'date percentage genetically modified cells sample collected'.
  - Rationale: Per best practices, fields that are written as 'date' in the question text should be updated to be specific to the parent question.

- **Updates made to applicable questions that includes the 'date' and 'lab value'.**
  - Data Move: Moved 'date' questions after the 'lab value' questions. For example, on F4001 / F4101, date question was moved after lab question.
  - Rationale: To standardize across forms.

- **Updates made to applicable questions that include the wording 'since the date of last report' / 'within the reporting period'.**
  - Update: Removed wording 'since the date of last report'/ 'within the reporting period' from the question text.
  - Rationale: This update was made to align with data capture best practices, as it should be understood that the applicable value (best/worst/highest/lowest/most recent) should come from assessments within the reporting period.

- **Updates made to applicable questions to remove 'unknown' option.**
  - Update: Removed 'unknown' option from the option list. For example, on F4000 / F4003 / F4101, 'unknown' option is removed.
  - Rationale: Updates to remove 'unknown' option to align with data capture best practices, when the 'unknown' option was not being selected.

- **Updates made to applicable questions to remove 'Be the Match' text.**
  - Update: Updated question text from 'Did NMDP/Be the Match facilitate the procurement, collection, or transportation of the product?' to 'Did NMDP facilitate the procurement, collection, or transportation of the product?
  - Rationale: Align with corporate rebranding and data capture best practices.

- **Updates made to remove questions related to COVID.**
  - Removal: Removed questions to capture data on COVID from F4000.
  - Rationale: This data is no longer relevant for research. Removing these questions reduces data burden.

- **Updates made to question "Name of cellular therapy product *(for most recent cell therapy infusion)*"**
  - Removal: This question is removed from F4003 R6, F4006 R7, F4101 R2.
  - Rationale: The question is removed because new validation functionality allows for this information to only be collected once and then used in validations on other forms.

- **Updates made to remove applicable parent questions containing known/unknown options.**
  - Update: Removed known / unknown parent question. For example, on F4003 and , removed parent questions asking whether date was known/unknown and leaving just the collection date and date of ANC recovery, respectively.
  - Rationale: Align with data capture best practices. The parent question was removed because the data being collected were known most of the time.

- **Updates made to remove disease and organism codes throughout CT forms.**
  - Update: Organism list was updated to remove organism codes from the option lists from F4000 . Diagnosis codes were removed from the Indication for Cellular Therapy options on F4000.
  - Rationale: Not necessary on form display, only for internal purposes per data capture best practices.

Pre-Cellular Therapy Essential Data (4000 R11)

Recipient Data

- **Q1 "Ethnicity", Q2 "Race *(check all that apply)*" on R10**
  - Removal: Removed questions.
    Rationale: These questions are removed because the ancestry data information are now captured on 'Race, Ethnicity and Ancestry' (F2807R1). These changes align with recent updates to the TED forms.

- **Q1 "Country of primary residence"**
  - Update: The following options were moved from "Country of primary residence" to "State/territory of residence of recipient *(for residents of USA)*":

    "American Samoa"

    "Guam"

    "Northern Mariana Islands"

    "Puerto Rico"

"United States Minor Outlying Islands"

"United States Virgin Islands"

- Rationale: These locations are not countries, but territories of the USA. These changes align with recent updates to the TED forms.

- **Q4 "State/territory of residence of recipient *(for residents of USA)*"**
  - Update: Question text updated from 'state of residence of recipient *(for residents of USA)*' to 'State/territory of residence of recipient *(for residents of USA)*'.
  - Rationale: The question text is updated to account for the US territories that have been added to the option list. These changes align with recent updates to the TED forms.

- **Q6 "Does the recipient require interpreter services? *(any interpreter for any level of care ex. reading / verbal)*"**
  - Addition: New question.
  - Rationale: Gathering data on the necessity and utilization of interpreter services is important for research in patient outcomes.

- **Q7 "Is the recipient an emancipated minor?", Q8 "Specify the recipient's current relationship status", Q9 "What is the highest degree or level of school that the recipient has completed?", Q10 "Is the recipient covered by health insurance?", Q11 "Specify type of health insurance *(check all that apply)*", Q14 "Specify other government program", & Q15 "Specify other health insurance"**
  - Addition: Added new questions to F4000. These questions were removed from F4001.
  - Rationale: Data regarding marital status, education and insurance is relevant to research and should be collected on a CTED-level form.

- **Q12 "Specify private insurance type"**
  - Addition: New question.
  - Rationale: Gathering more specific data on the type of private insurance a recipient has is important for research in patient outcomes.

- **Q13 "Specify Medicare type"**
  - Addition: New question.
  - Rationale: Gathering more specific data on the Medicare type a recipient has is important for research in patient outcomes.

- **Q17 "Sponsor"**
  - Update: The question text updated from 'study sponsor' to 'sponsor'.
  - Rationale: The updated question text accounts for both clinical trials and studies without a clinical trial component.

  - Update: The option 'PedAL' is removed from the option list.
  - Rationale: This option was removed from the option list because 'PedAL' is a COG study and can be reported under COG option.

- Update: The following options 'PTCTC' and 'SWOG' were added to the option list.
- Rationale: These new options align with recent updates to Pre-Transplant Essential Data (F2400R11) and may have future cellular therapy studies.

Cellular Therapy and HCT History

- **Q31 "Was the prior cellular therapy performed at a CIBMTR Affiliated Network Center?" & Q32 "CIBMTR Center Number (CCN)"**
  - Addition: Added new questions to capture if the recipient's prior cellular therapy was performed at a CIBMTR Affiliated Network Center. If the answer is "yes" then the center can be selected from a dropdown list instead of entering the name and location of the center.
  - Rationale: These questions have new functionality so sites can select affiliated sites and have details populate the field. This should reduce burden and improve data quality internally.

- **Q34 "Specify the primary indication for the prior cellular therapy"**
  - Update: Removed the floating text 'Post-HCT' from the options 'Prevent disease relapse' and 'Suboptimal donor chimerism'.
  - Rationale: The floating text is removed because these options are no longer limited to Post-HCT.

- **Q38 "Specify the number of prior HCTs"**
  - Addition: New question.
  - Rationale: This change aligns with recent updates to Pre-Transplant Essential Data (F2400R11).

- **Q42 "Was the prior HCT performed at a CIBMTR Affiliated Network Center?" Q43 "CIBMTR Center Number (CCN)"**
  - Addition: Added new questions to capture if the recipient's prior HCT was performed at a CIBMTR Affiliated Network Center. If the answer is "yes" then the center can be selected from a dropdown list instead of entering the name and location of the center.
  - Rationale: These questions have new functionality so sites can select affiliated sites and have details populate the field. This should reduce burden and improve data quality internally.

Product Identification

- **Q50 "Specify the related donor type *(allogeneic, related only)*"**
  - Update: Added floating text to the following options:
    HLA-matched other relative to HLA-matched other relative (does NOT include a haplo-identical donor)
    HLA-mismatched relative to HLA-mismatched relative (includes haplo-identical donor)
  - Rationale: To provide further clarity and aligns with recent updates to Pre-Transplant Essential Data (F2400R11).

- **Q56 "Registry or UCB Bank ID'"**
  - Update: The Registry/UCB bank list has been updated with the WMDA-maintained global database of Search & Match Service, which provides an ION, or Issuing Organization Number, that uniquely describes the organization that provided the product. All options were reviewed and updated with current names and code numbers.
  - Rationale: This information is needed to link donor and recipient data to be able to provide limited outcomes data back to Cord Blood Banks and Donor Centers. These options were updated to collect correct, relevant data. These changes align with recent updates to the TED form 2400.

- **Q64 "Name of cellular therapy product *(for most recent cell therapy infusion)*"**
  - Update:
    - Updated option list by adding new options:
      - Anitocabtagene autoleucel
      - Arlocabtagene autoleucel
      - Lifileucel (Amtagvi®)
      - Obecabtagene autoleucel (Aucatzyl®)
      - Rapcabtagene autoleucel
      - Relmacabtagene autoleucel (Carteyva®)
      - Tabelecleucel (Ebvallo™)
      - Zamtocabtagene autoleucel
      - Zevorcabtagene autoleucel
    - Added a brand name '(Tecelra®)' to the option 'Afamitresgene autoleucel'.
  - Rationale: These newer options are included in the option list to align with current approved and investigational cell therapy products. Brand names are added as they become available.

Indication for Cellular Therapy

- **Q66 "What was the primary indication for performing treatment with cellular therapy?"**
  - Update: Removed floating text 'Post-HCT' from the option 'Prevent disease relapse'.
  - Rationale: The floating text is removed because the indication is no longer limited to post-HCT.

  - Update: Removed the option 'Suboptimal donor chimerism (post-HCT)' from the option list.
  - Rationale: The option is removed because it is no longer relevant in context of CT as it is applicable to DLI.

- **After Q77 "Specify the organism for which the cellular therapy is being given to treat"**

F4000R10	Data Change Description	F4000R11	Rationale
	Addition	Gram negative bacteria including Pseudomonas aeruginosa	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with clinically relevant organisms commonly identified in laboratory reports
	Addition	Gram positive bacteria including Staphylococcus aureus	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with clinically relevant organisms commonly identified in laboratory reports
	Addition	Mycobacterium avium complex	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with clinically relevant organisms commonly identified in laboratory reports
	Addition	Mycobacterium tuberculosis	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with clinically relevant organisms commonly identified in laboratory reports

	Addition	Mycobacterium NOS	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with clinically relevant organisms commonly identified in laboratory reports
Blastomyces (dermatitidis)	Update: retire and add new	Blastomyces (all species, including dermatitidis)	Updated the option text to standardize across the forms
Histoplasma (capsulatum)	Update: retire and add new	Histoplasma (all species, including capsulatum)	Updated the option text to standardize across the forms
	Addition	Lomentospora prolificans	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with clinically relevant organisms commonly identified in laboratory reports
Mucorales (all species)	Replacement	Mucorales (all species including Rhizopus, Mucor, Rhizomucor, Absidia, Lichtheimia, Cunninghamella species)	Updated the organisms to list the words that data managers are likely to see in the lab report
Rhizopus (all species)	Removal		'Rhizopus' is part of the option "Mucorales"
Zygomycetes, NOS	Removal		This was an old term for "Mucorales", but won't be used by any labs now
Enterovirus (ECHO, Coxsackie)	Update: retired and add new	Enterovirus except polioviruses and D68	These options are now grouped together under

Enterovirus, NOS		(including echoviruses and coxsackieviruses)	the updated Enterovirus entry
Enterovirus (polio)	Replacement	Polioviruses	This option is a group of species. Most accurate to call it "Polioviruses"
Hepatitis E	Replacement	Hepatitis E virus	Updated the option text to account for virus terminology
	Addition	Zika Virus	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with clinically relevant organisms commonly identified in laboratory reports
	Addition	Cryptosporidium	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with clinically relevant organisms commonly identified in laboratory reports
	Addition	Malaria	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with clinically relevant organisms commonly identified in laboratory reports

- **After Q77 "Specify the organism for which the cellular therapy is being given to treat"**

- Update: Reordered the organism list.
- Rationale: The organism list is reordered to group various organisms based on their biological classifications (bacteria, fungi, virus, other) and list alphabetically within each group.

Holding / Bridging Therapy Prior to Infusion

- **Holding / Bridging Therapy Prior to Infusion, Q86 "Did the recipient receive holding / bridging therapy prior to infusion?",Q87 "Type of holding / bridging therapy *(check all that apply)*", Q88 "Date holding / bridging therapy started", Q89 "Date holding / bridging therapy started", Q90 "Date holding / bridging therapy stopped", Q91 "Date holding / bridging therapy stopped"**
  - Addition: New section and questions.
  - Rationale: The new section and questions are added because understanding the timing of holding / bridging therapy is an evolving area of interest for research.

Lymphodepleting Therapy Prior to Cellular Therapy

- **Q93 "Height at start of lymphodepleting therapy", Q94 "Actual weight at start of lymphodepleting therapy", Q95 "Drug", Q96 "Specify other drug", Q97 "Total prescribed dose", & Q98 "Date started"**
  - Addition: Moved questions from the section 'lymphodepleting therapy prior to cellular therapy' from F4001 to F4000.
  - Rationale: The questions were moved because it is relevant for research and should be collected on a CTED-level form.

- **Q95 "Drug"**
  - Update: Added a new option 'Cladribine' to the option list.
  - Rationale: The list is updated to align with current therapy regimens. The new option is highly reported in the 'specify other drug' field.

  - Update: Removed the options 'Ifosfamide' and 'Propylene glycol-free melphalan (Evomela) from the option list.
  - Rationale: The options are removed as no longer relevant to lymphodepleting therapy.

- **Q97 "Total prescribed dose"**
  - Update: Added a new unit of measure 'mg/kg' as well as checkboxes to the units of measures (mg/kg, mg/m^2).
  - Rationale: Added a common unit of measure for the dosing of these drugs. Added checkboxes to easily report the unit of measure.

Hematologic Findings Prior to Lymphodepleting Therapy

- **Q99 "LDH *(report LDH value immediately prior to lymphodepleting therapy)*"**

- Update: Updated the floating text from 'report most recent LDH value within 30 days of lymphodepleting therapy' to 'report LDH value immediately prior to lymphodepleting therapy'.
- Rationale: Although LDH is not collected on 2400, aligns to updates for similar labs on TED forms.

- **Q101 "Date sample collected"**
  - Update: New question.
  - Rationale: It is important to know the date sample collected because within 30 days qualifier was removed, it is important to capture the date collected.

Comorbid Conditions

- **Q107 "Prior viral exposure / infection *(check all that apply)*"**

F4000R10	Data Change Description	F4000R11	Rationale
Anti-EBV (Epstein-Barr virus antibody)	Replacement	Anti-EBV (Epstein-Barr virus IgG and / or EBNA antibody)	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with terminology in laboratory reports
	Addition	CMV IgG (cytomegalovirus IgG antibody)	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with terminology in laboratory reports
Hepatitis B surface antibody	Replacement	HbsAb (hepatitis B surface antibody)	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with

			terminology in laboratory reports
Toxoplasmosis antibody	Replacement	Toxoplasma IgG (Toxoplasma antibody)	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with terminology in laboratory reports
Not applicable (all viral testing negative)	Replacement	Not applicable (all baseline serology/NAATs negative)	The option list is revised in accordance with recommendations from the Infection working committee to ensure alignment with terminology in laboratory reports

- **Q108 "Did the recipient have a prior malignancy?"**
  - Addition: New question.
  - Rationale: The question was added because it was determined that information about any prior malignancy and treatment is relevant to research. Aligns with changes to the Pre-Transplant Essential Data (F2400).

- **Q109 "Specify prior malignancy *(check all that apply)*", Q110 "Specify other hematologic malignancy: *(prior)*", & Q111 "Specify other solid tumor: *(prior)*"**
  - Data Move: The question to capture prior malignancy was moved so that it comes before the question capturing HCT comorbidity index (Sorror Score).
  - Rationale: Some of these prior malignancies are not included in the HCT comorbidity index (Sorror Score) and could be missed if prior malignancy was not selected within the Sorror Score. However, knowing if a recipient had any of these prior malignancies is important for prognostic and outcomes research.

- **Q112 "Was the prior malignancy treated?"**
  - Addition: New question.
  - Rationale: It is relevant to research to capture if a prior malignancy was treated or not.

- **Q113 "Were there any co-existing diseases or organ impairment present according to the HCT comorbidity index (HCT-CI)? *(within 6 months prior to the infusion, unless noted as ANY history in the list of coexisting diseases) Source:***

***Sorror, M. L. (2013). How I assess comorbidities before hematopoietic cell transplantation. Blood, 121(15), 2854-2863. For the full description of each comorbidity, please review Appendix J in the Forms Instruction Manual*"**
  - Update: Updated instructional text by adding hyperlink to Appendix J: 'For the full description of each comorbidity, please review Appendix J in the Forms Instruction Manual'.
  - Rationale: The hyperlink is added to the instructional text for ease of manual navigation.

- **Q114 "Specify co-existing diseases or organ impairment *(check all that apply)*"**
  - Update: Removed floating text from the option list.
  - Rationale: Removing descriptions of the comorbidities from the form and only having them in the Forms Instruction Manual will allow CIBMTR to more quickly update any changes to the descriptions as research advances.

  - Update: Removed option 'prior malignancy' from the option list.
  - Rationale: The option is removed because 'specify prior malignancy' question is captured outside HCT comorbidity index.

- **Q116 "Did the recipient have a prior solid organ transplant?", Q117 "Specify organ", Q118 "Specify other organ", Q119 "Year of prior solid organ transplant"**
  - Addition: New questions.
  - Rationale: Aligns with recent updates to TED forms.

Pre-Cellular Therapy Baseline Data (4001 R2)

Lymphodepleting Therapy Prior to Cellular Therapy

- **Q5 "Height at start of lymphodepleting therapy",Q6 "Actual weight at start of lymphodepleting therapy",Q7 "Drug",Q8 "Specify other drug",Q9 "Total prescribed dose", & Q10 "Date started" on R1**
  - Update: Removed the questions.
  - Rationale: The questions were moved to the Pre-Cellular Therapy Essential Data (4000) form.

Toxicity Prophylaxis

- **Q5 "Therapy given for the prevention of CRS" *(prophylactic therapy) (check all that apply)***
  - Update: Removed option 'Itacitinib' from the option list.
  - Rationale: The option is removed because the product was taken off the market.

- **Q5 "Therapy given for the prevention of CRS" *(prophylactic therapy) (check all that apply)* & Q7 "Therapy given for the prevention of neurotoxicity" *(prophylactic therapy) (check all that apply)***

- Update: Added new options 'Corticosteroids', 'Dasatinib', 'Duvelisib', 'Emapalumab', 'Ruxolitinib' to the option list.
- Rationale: The new options are added to align with current therapy regimen used for toxicity prophylaxis.

Hematologic Findings Prior to Lymphodepleting Therapy

- **Q22 "C-reactive protein"**
  - Update: Removed floating text 'report most recent value prior to lymphodepleting therapy' from the question text.
  - Rationale: The floating text is removed because it is captured as instructional text.

Socioeconomic Information

- **Q34 "Is the recipient an adult (18 years of age or older) or emancipated minor?", Q35 "Specify the recipient's marital status", Q39 "What is the highest educational grade the recipient completed?", Q41 "Is the recipient covered by health insurance?", Q42 "Specify type of health insurance", Q43 "Specify other governmental program", & Q44 "Specify other health insurance" on R1**
  - Removal: Removed the questions.
  - Rationale: These questions were moved to Pre-cellular Therapy Essential Data (4000) form.

- **Q45 "Specify the recipient's combined household gross annual income *(include earnings by all family members living in the household before taxes) (For U.S. residents only)*", & Q46 "Number of people living in the household", Q47 "Number of people living in the household under the age of 18" on R1**
  - Removal: Removed the questions.
  - Rationale: This information is typically not easily found in the EMR and the questions are being removed to reduce burden.

Cellular Therapy Product (4003 R6)

Cell Product Source

- **Key Field: Donor Sex**
  - Update: 'Unknown' option is added to the key fields of donor sex.
  - Rationale: 'Unknown' option is added because this information is not always available for "off the shelf" products.

- **Q3 "What is the tissue source of the cellular product? *(check all that apply)*"**
  - Update: Removed 'Adipose tissue', 'Amniotic fluid', 'Cardiac tissue', 'Hepatic tissue', 'Induced pluripotent stem cells (IPSC)', 'Lymph node', 'Neuronal tissue', 'Ophthalmic tissue', 'Pancreatic tissue' 'Placenta', 'Umbilical cord', 'Unknown' from the option list.

- Rationale: These options were removed because a review of the data indicated that removed options were never selected.

- **Q5 "What is the cell type? *(check all that apply)*"**
  - Update: Removed 'Cardiac Progenitor cells', 'Dendritic cells / tumor cell hybridomas (tumor vaccines)', 'Endothelial progenitor cells', 'Human umbilical cord perivascular (HUCPV) cells', 'Islet cells', 'Natural killer cells (NK cells)', 'Oligodendrocytes' from the option list.
  - Rationale: Theses options were removed because the review of data indicated that removed options were never selected.

- **Q9 "Specify pharmaceutical / biotech company"**
  - Update: Added following options to the option list:
    - Adaptimmune
    - AlloVir
    - Autolus
    - CRISPR Therapeutics
    - FATE Therapeutics
    - Marker Therapeutics
    - Orca Biosystems
    - Poseida Therapeutics, Inc
    - Rapa Therapeutics
  - Rationale: These options were added to ensure the option list aligns with current pharmaceutical and biotech companies.

Collection Procedure

- **Q11 "Specify the method of product collection"**
  - Update: Updated option from 'Leukapheresis' to 'Apheresis/Leukapheresis'.
  - Rationale: 'Apheresis' is frequently mentioned in the category of 'specify other method' field. Also, the scientific director decided for purposes of this data collection these could be considered one category as leukapheresis is a type of apheresis.

Cell Product Manipulation

- **Q22 "Specify the gene edited *(check all that apply)*"**
  - Update: Updated question text from 'Specify the gene edited' to 'Specify the gene edited (check all that apply)'.
  - Rationale: Revised the question by adding 'check all that apply' so multiple gene edits can be selected. For instance, HLA / TCR was frequently mentioned under 'specify other gene'.

- **Q33 "Specify the tumor / cancer antigen *(check all that apply)"***
  - Update: Added following options 'Claudin6', 'Claudin18.2', 'EGFRvIII', 'EphrinA2', 'Folate receptor alpha', 'IL13Ra2', 'Mutant KRAS for TCR', 'ROR1' to the option list.

- Rationale: The new options are added to align with current targets specific to tumor / cancer antigens.

Cell Product Analysis

- **Q45 "Method of testing cell viability" & Q46 "Specify other method" on R5**
  - Update: Removed the following questions 'Method of testing cell viability' and 'Specify other method'.
  - Rationale: The questions are removed as no longer relevant.

Cellular Therapy Infusion (4006 R7)

Product Infusion

- **Q7 "Specify what happened to the reserved portion *(check all that apply)*"**
  - Update: New options 'Research' and 'Training or Quality Control' are added to the option list.
  - Rationale: Aligns with recent updates to Hematopoietic Cellular Transplant (HCT) Infusion (F2006).

- **Q9 "Specify the route of product infusion"**
  - Update: Updated the option from 'Intrathecal' to 'Intrathecal / Intra-ventricular'.
  - Rationale: Intra-ventricular was frequently reported as "other". Rather than create an additional separate entry, the scientific director decided that it could be collected together with intrathecal as both terms are related to delivery to the brain / spinal cord."

- **Q15 "Specify the cell type(s) administered *(check all that apply)*"**
  - Update: Removed 'Cardiac Progenitor cells', 'Dendritic cells / tumor cell hybridomas (tumor vaccines)', 'Endothelial progenitor cells', 'Human umbilical cord perivascular (HUCPV) cells', 'Islet cells', 'Natural killer cells (NK cells)', 'Oligodendrocytes' from the option list.
  - Rationale: The review of the data indicates that removed options were never selected and to align with updates to Cellular Therapy Product (4003) form.

- **Q21 "Total number of cardiac progenitor cells", Q22 "Total number of dendritic / hybridoma tumor cells", Q23 "Total number of endothelial progenitor cells", Q24 "Total number of HUCPV cells", Q25 "Total number of islet cells", Q27 "Total number of NK cells", & Q28 "Total number of oligodendrocytes" on R6**
  - Update: Removed questions.
  - Rationale: The review of the data indicates that removed options were never selected and to align with updates to Cellular Therapy Product (4003) form.

Concomitant Therapy

- **Q26 "Specify drugs"**
  - Update: Removed the option 'GM-CSF' from the option list.
  - Rationale: The option is removed because no longer used for concomitant therapy for CT research.

Post-Cellular Therapy Follow-Up (4101 R2)

Disease Relapse or Progression

- **Q4 "Was there evidence of antigen escape?"**
  - Update: Added a new option 'not applicable' to the option list.
  - Rationale: The new option is added to account for situations without measurable residual disease.

Persistence of Cells

- **Q42 "Were B-cell counts monitored after infusion?"**
  - Update: 'Unknown' option was added to the option list.
  - Rationale: 'Unknown' option was requested to be added as an additional option to ensure data accuracy.

- **Q45 "Did the recipient receive a subsequent infusion for loss of B-cell aplasia?"**
  - Addition: New question.
  - Rationale: Added to question to know if the subsequent infusion was given for the indication of "loss of B-cell aplasia".